Preclinical Qualification of a New Multi-antigen Candidate Vaccine for Metastatic Melanoma

Thorsten U. Vogel,Lucian Visan,Belma Ljutic,Beata Gajewska,Judy Caterini,Danielle Salha,Tao Wen,Liwei He,Mark Parrington,Shi Xian Cao,Bryan McNeil,Devender Sandhu,Nancy Scollard,Linong Zhang,Bill Bradley,Mei Tang,Corey Lovitt,Ray Oomen,Pamela Dunn,Jim Tartaglia,Neil Berinstein

Preclinical Qualification of a New Multi-antigen Candidate Vaccine for Metastatic Melanoma

2010

New therapies are urgently required for the treatment of patients with melanoma. Here we describe the generation and preclinical evaluation of 3 new recombinant ALVAC(2) poxviruses vCP2264, vCP2291, and vCP2292 for their ability to induce the desired cellular immune responses against the encoded mel

Keywords:

Melanoma
Virology
Immunology
Immune system
Antigen
Cancer
Immunotherapy
Metastasis
Recombinant DNA
Medicine
metastatic melanoma
advanced stage

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations